September 30, 2021
J Diagn Treat Oral Maxillofac Pathol 2021;106–110.
Under a Creative Commons license
Tymofieiev OO, Sokoliuk MA, Ripa VM, Havlytiuk DS, Kolisnichenko LA. Usage of the medical product Ketanov in the maxillofacial surgery. J Diagn Treat Oral Maxillofac Pathol 2021;5(9):106–10.
Pain is the psychophysiological condition of a person arising in as a result of the action of ultra-strong or destructive irritants causing organic or functional disturbances in the organism. The purpose of our research was to evaluate analgesic efficiency of the medicinal product ketanov (ketorolac tromethamine), produced by the firm “Ranbaxy” in patients with diseases of the maxillofacial region. We monitored 127 cases, which we divided into the following groups: Group I of 44 patients after performing dental surgery (extraction of tumors and tumor-like formations of jaws and soft tissues, plastic and reconstructive operations); Group II – 23 patients with mandibular fractures; Group III – 27 patients with inflammatory diseases of the soft tissues; Group IV – 19 patients with rhythmic diseases of the maxillofacial region (odontogenic neuralgia, post-traumatic and post-operative neuralgo-neuritis); Group V – 14 patients who have undergone the surgical phase of dental implantation. Ketanov (ketorolac tromethamine) is a highly effective analgesic and is recommended for use in the post-operative period after removal of tumors and tumor-like formations of the jaws and soft tissues of the face and neck, after plastic and reconstructive operations, in case of jaw fractures, purulent inflammatory processes, odontogenic neuralgia, postoperative and post-traumatic neuralgo-neuritis of peripheral branches of the trigeminal nerve, as well as after the surgical stage of dental implantation.